Eupraxia Pharmaceuticals Inc.
Financial Statements (IFRS) · Amounts in CAD
Income Statement
Balance Sheet
Cash Flow
| Line Item | FY 2024Dec 31, 2024 | FY 2023Dec 31, 2023 | FY 2022Dec 31, 2022 | FY 2021Dec 31, 2021 |
|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling General And Administration | 10.9M | 7.5M | 4.0M | 7.0M |
| General And Administrative Expense | 10.9M | 7.5M | 4.0M | 7.0M |
| Research And Development | 16.1M | 20.4M | 13.6M | 7.6M |
| Depreciation And Amortization In Income Statement | -- | -- | 142,406 | 87,472 |
| Other Operating Expenses | -- | -- | 156,596 | 7,267 |
| Operating Expense | 27.0M | 27.8M | 17.6M | 14.6M |
| Operating Income | -27.0M | -27.8M | -17.6M | -14.6M |
| EBIT | -25.1M | -27.8M | -18.0M | -17.3M |
| Interest Expense | 603,573 | 1.2M | 982,856 | 1.0M |
| Interest Expense Non Operating | 603,573 | 1.2M | 982,856 | 1.0M |
| Interest Income | 1.2M | 862,969 | 431,799 | 51,551 |
| Interest Income Non Operating | 1.2M | 862,969 | 431,799 | 51,551 |
| Net Interest Income | 556,370 | -307,204 | -551,057 | -965,444 |
| Other Income Expense | 704,356 | -775,150 | -822,255 | -2.7M |
| Other Non Operating Income Expenses | -- | -- | -- | -1.8M |
| Special Income Charges | -336,971 | -4,846 | -6,637 | 0.00 |
| Gain On Sale Of Security | 1.0M | -770,304 | -815,618 | -941,504 |
| Pretax Income | -25.7M | -28.9M | -19.0M | -18.3M |
| Tax Provision | 1,804 | 36,423 | 0.00 | -- |
| Tax Effect Of Unusual Items | 105,653 | -310,060 | 0.00 | 0.00 |
| Net Income From Continuing And Discontinued Operation | -25.5M | -28.2M | -18.5M | -18.0M |
| Net Income From Continuing Operation Net Minority Interest | -25.5M | -28.2M | -18.5M | -18.0M |
| Net Income Including Noncontrolling Interests | -25.7M | -29.0M | -19.0M | -18.3M |
| Minority Interests | 241,953 | 745,210 | 501,135 | 297,991 |
| Net Income Common Stockholders | -25.5M | -28.2M | -18.5M | -18.0M |
| Net Income | -25.5M | -28.2M | -18.5M | -18.0M |
| EBITDA | -25.0M | -27.6M | -17.9M | -17.2M |
| Normalized EBITDA | -25.7M | -26.8M | -17.0M | -16.3M |
| Reconciled Depreciation | 171,719 | 155,527 | 147,894 | 87,472 |
| Basic EPS | -0.76 | -1.17 | -0.96 | -1.47 |
| Diluted EPS | -0.76 | -1.17 | -0.96 | -1.47 |
| Basic Average Shares | 33.9M | 24.1M | 19.3M | 12.4M |
| Diluted Average Shares | 33.9M | 24.1M | 19.3M | 12.4M |
| Total Unusual Items | 704,356 | -775,150 | -822,255 | -941,504 |
| Total Unusual Items Excluding Goodwill | 704,356 | -775,150 | -822,255 | -941,504 |
| Tax Rate For Calcs | 0.15 | 0.40 | 0.00 | 0.00 |
| Normalized Income | -26.1M | -27.8M | -17.7M | -17.1M |
| Depreciation Amortization Depletion Income Statement | -- | -- | 142,406 | 87,472 |
| Depreciation Income Statement | -- | -- | 142,406 | 87,472 |
| Diluted NI Availto Com Stockholders | -25.5M | -28.2M | -18.5M | -18.0M |
| Gain On Sale Of Ppe | 18,611 | -4,846 | -6,637 | 0.00 |
| Insurance And Claims | 954,392 | 367,472 | 357,763 | 283,364 |
| Net Income Continuous Operations | -25.7M | -29.0M | -19.0M | -18.3M |
| Net Non Operating Interest Income Expense | 556,370 | -307,204 | -551,057 | -965,444 |
| Other Gand A | 4.8M | 4.2M | 936,028 | 1.5M |
| Other Special Charges | 355,582 | -- | -- | -- |
| Salaries And Wages | 5.2M | 3.0M | 2.7M | 5.2M |
| Total Expenses | 27.0M | 27.8M | 17.6M | 14.6M |
| Line Item | FY 2024Dec 31, 2024 | FY 2023Dec 31, 2023 | FY 2022Dec 31, 2022 | FY 2021Dec 31, 2021 |
|---|---|---|---|---|
| Cash And Cash Equivalents | 33.1M | 19.3M | 18.3M | 16.4M |
| Cash Cash Equivalents And Short Term Investments | 33.1M | 19.3M | 18.3M | 23.5M |
| Cash Financial | 33.1M | 19.3M | -- | -- |
| Other Short Term Investments | -- | -- | 0.00 | 7.1M |
| Receivables | 228,872 | 190,612 | 89,715 | 337,028 |
| Prepaid Assets | 1.1M | 270,710 | 235,903 | 212,535 |
| Current Assets | 34.4M | 19.8M | 18.6M | 24.0M |
| Gross PPE | 884,606 | 854,312 | 823,560 | 708,732 |
| Accumulated Depreciation | -459,690 | -398,065 | -292,810 | -246,726 |
| Net PPE | 424,916 | 456,247 | 530,750 | 462,007 |
| Total Non Current Assets | 505,677 | 463,151 | 533,242 | 486,611 |
| Total Assets | 34.9M | 20.3M | 19.1M | 24.5M |
| Current Debt | -- | 10.4M | 79,418 | 74,443 |
| Current Debt And Capital Lease Obligation | 71,859 | 10.5M | 129,821 | 121,409 |
| Payables | -- | 5.0M | -- | -- |
| Payables And Accrued Expenses | 1.5M | 8.1M | 2.4M | 1.1M |
| Current Accrued Expenses | 1.5M | 3.0M | 2.4M | 1.1M |
| Current Liabilities | 3.1M | 19.4M | 3.1M | 1.8M |
| Long Term Debt | -- | -- | 8.8M | 7.3M |
| Long Term Debt And Capital Lease Obligation | -- | 0.00 | 8.9M | 7.4M |
| Long Term Capital Lease Obligation | -- | 0.00 | 51,303 | 108,038 |
| Total Non Current Liabilities Net Minority Interest | 0.00 | 0.00 | 8.9M | 7.4M |
| Total Liabilities Net Minority Interest | 3.1M | 19.4M | 11.9M | 9.2M |
| Common Stock | 116.4M | 92.9M | 71.0M | 63.3M |
| Capital Stock | 148.1M | 92.9M | 71.0M | 63.3M |
| Additional Paid In Capital | 20.5M | 17.5M | 16.9M | 10.9M |
| Retained Earnings | -131.0M | -105.5M | -77.3M | -58.2M |
| Gains Losses Not Affecting Retained Earnings | -4.2M | -2.7M | -2.8M | -- |
| Other Equity Adjustments | -4.2M | -2.7M | -2.8M | -- |
| Common Stock Equity | 1.7M | 2.2M | 7.8M | 16.0M |
| Stockholders Equity | 33.4M | 2.2M | 7.8M | 16.0M |
| Total Equity Gross Minority Interest | 31.8M | 892,326 | 7.2M | 15.3M |
| Minority Interest | -1.6M | -1.3M | -578,671 | -653,979 |
| Total Capitalization | 33.4M | 2.2M | 16.6M | 23.3M |
| Net Tangible Assets | 33.4M | 2.2M | 7.8M | 16.0M |
| Tangible Book Value | 1.7M | 2.2M | 7.8M | 16.0M |
| Working Capital | 31.3M | 429,175 | 15.5M | 22.2M |
| Invested Capital | 1.7M | 12.6M | 16.7M | 23.3M |
| Total Debt | 71,859 | 10.5M | 9.0M | 7.5M |
| Share Issued | 35.6M | 27.3M | 21.6M | 14.2M |
| Ordinary Shares Number | 35.6M | 27.3M | 21.6M | 14.2M |
| Buildings And Improvements | -- | -- | 89,931 | 92,888 |
| Capital Lease Obligations | 71,859 | 53,316 | 101,706 | 155,005 |
| Current Capital Lease Obligation | 71,859 | 53,316 | 50,403 | 46,966 |
| Current Deferred Liabilities | -- | -- | -- | 0.00 |
| Derivative Product Liabilities | -- | -- | -- | 0.00 |
| Dueto Related Parties Current | -- | -- | -- | 0.00 |
| Leases | 118,359 | 128,767 | 125,744 | 133,573 |
| Machinery Furniture Equipment | 139,606 | 153,621 | 136,977 | 101,177 |
| Non Current Prepaid Assets | 80,761 | 6,904 | 2,492 | 24,604 |
| Other Current Borrowings | -- | 10.4M | 79,418 | 74,443 |
| Other Payable | -- | 5.0M | -- | -- |
| Other Properties | 626,641 | 571,924 | 560,839 | 473,982 |
| Other Receivables | -- | -- | 13,892 | 314,910 |
| Pensionand Other Post Retirement Benefit Plans Current | 1.5M | 858,628 | 513,301 | 583,141 |
| Preferred Stock | 31.7M | 0.00 | -- | -- |
| Preferred Stock Equity | 31.7M | -- | -- | -- |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| Taxes Receivable | 228,872 | 190,612 | 75,823 | 22,119 |
| Total Tax Payable | 0.00 | 36,423 | 0.00 | -- |
| Line Item | FY 2024Dec 31, 2024 | FY 2023Dec 31, 2023 | FY 2022Dec 31, 2022 | FY 2021Dec 31, 2021 |
|---|---|---|---|---|
| Operating Cash Flow | -30.0M | -20.7M | -14.4M | -11.5M |
| Cash Flow From Continuing Operating Activities | -30.0M | -20.7M | -14.4M | -11.5M |
| Depreciation And Amortization | 171,719 | 155,527 | 147,894 | 87,472 |
| Depreciation Amortization Depletion | 171,719 | 155,527 | 147,894 | 87,472 |
| Stock Based Compensation | 3.2M | 1.4M | 1.4M | 3.3M |
| Change In Working Capital | -6.8M | 5.4M | 1.5M | -165,826 |
| Change In Receivables | -101,389 | -103,710 | 230,481 | 149,714 |
| Change In Payables And Accrued Expense | -5.7M | 5.6M | 1.3M | -366,649 |
| Change In Payable | -5.7M | 5.6M | 1.3M | -- |
| Other Non Cash Items | 182,569 | 521,008 | 659,951 | 2.7M |
| Capital Expenditure | -104,227 | -73,377 | -235,550 | -338,562 |
| Purchase Of PPE | -104,227 | -73,377 | -235,550 | -338,562 |
| Net PPE Purchase And Sale | -75,159 | -73,377 | -235,308 | -338,562 |
| Purchase Of Investment | -- | 0.00 | -3.3M | -7.1M |
| Sale Of Investment | -- | 0.00 | 13.3M | 0.00 |
| Net Investment Purchase And Sale | -- | 0.00 | 10.1M | -7.1M |
| Investing Cash Flow | -75,159 | -73,377 | 9.8M | -11.3M |
| Cash Flow From Continuing Investing Activities | -75,159 | -73,377 | 9.8M | -11.3M |
| Issuance Of Debt | -- | -- | 0.00 | 9.9M |
| Repayment Of Debt | -9.1M | -79,441 | -142,268 | -459,935 |
| Net Issuance Payments Of Debt | -9.1M | -79,441 | -142,268 | 9.5M |
| Issuance Of Capital Stock | 54.6M | 15.9M | 10.6M | 29.7M |
| Net Common Stock Issuance | 54.6M | 15.9M | 10.6M | 29.7M |
| Financing Cash Flow | 45.8M | 21.1M | 10.8M | 39.1M |
| Cash Flow From Continuing Financing Activities | 45.8M | 21.1M | 10.8M | 39.1M |
| Effect Of Exchange Rate Changes | -2.0M | 821,397 | -507,395 | -64,020 |
| Changes In Cash | 15.7M | 256,970 | 6.2M | 16.3M |
| Beginning Cash Position | 19.3M | 18.3M | 12.5M | 117,744 |
| End Cash Position | 33.1M | 19.3M | 18.3M | 16.4M |
| Free Cash Flow | -30.1M | -20.8M | -14.6M | -11.8M |
| Interest Paid Supplemental Data | 393,739 | 598,046 | -- | -- |
| Change In Account Payable | -714,878 | 577,908 | 1.3M | -- |
| Change In Prepaid Assets | -948,422 | -122,435 | -39,959 | 51,110 |
| Common Stock Issuance | 54.6M | 15.9M | 10.6M | 29.7M |
| Depreciation | 171,719 | 155,527 | 147,894 | 87,472 |
| Gain Loss On Investment Securities | -- | -- | -- | 998,589 |
| Gain Loss On Sale Of PPE | -18,611 | 4,846 | 6,879 | 0.00 |
| Long Term Debt Issuance | -- | -- | 0.00 | 9.9M |
| Long Term Debt Payments | -62,651 | -79,441 | -142,268 | -459,935 |
| Net Foreign Currency Exchange Gain Loss | 156,087 | -64,609 | -223,709 | -54,002 |
| Net Income From Continuing Operations | -25.7M | -29.0M | -19.0M | -18.3M |
| Net Long Term Debt Issuance | -62,651 | -79,441 | -142,268 | 9.5M |
| Net Other Investing Changes | -- | -- | -- | -3.9M |
| Net Short Term Debt Issuance | -9.1M | 0.00 | -- | -- |
| Operating Gains Losses | 137,476 | -59,763 | -216,830 | 944,587 |
| Proceeds From Stock Option Exercised | 363,061 | 5.3M | 306,770 | 0.00 |
| Sale Of PPE | 29,068 | 0.00 | 242.00 | 0.00 |
| Short Term Debt Payments | -9.1M | 0.00 | -- | -- |
| Unrealized Gain Loss On Investment Securities | -1.2M | 836,595 | 1.1M | -- |